More Intensive Regimen Doesn't Prolong Survival in Gastric Cancer

Share this content:

the Cancer Therapy Advisor take:

Compared with surgery alone, adjuvant fluoropirimidine, either with or without platinum compounds, has demonstrated benefits in previous studies.

 

To further assess its potential, researchers evaluated whether disease-free survival improved with sequential FOLFIRI [irinotecan plus 5-fluorouracil/folinic acid (5-FU/LV)] followed by docetaxel plus cisplatin when compared with 5-FU/LV alone in patients who underwent surgery for gastric cancer.

 

A total of 1,100 patients with resectable adenocarcinoma of the stomach or gastroesophageal junction were randomly assigned sequential FOLFIRI followed by docetaxel or a De Gramont regimen (5-FU/LV).

 

After a median follow-up of 57.4 months, 297 patients in the sequential arm and 284 patients in the 5-FU/LV arm died or experienced recurrence, and 243 in the sequential arm and 240 in the 5-FU/LV arm died.

 

Disease-free survival and overall survival were not significantly different between the two study groups, according to the study results. At 5 years, disease-free survival and overall survival were 44.6% and 44.6% in the sequential arm and 51% and 50.6% in the 5-FU/LV arm.

 

These findings prompted the researchers to conclude that the more intensive regimen did not improve disease-free survival or overall survival when compared with monotherapy in this patient population.

 

Further study may yield different results, but for now, it appears that monotherapy may be the better course of action in patients with radically resected gastric cancer.

miniDOX Chemotherapy for Patients with Advanced Gastric Cancer
More Intensive Regimen Doesn't Prolong Survival in Gastric Cancer
Some trial have demonstrated a benefit of adjuvant fluoropirimidine with or without platinum compounds compared with surgery alone. ITACA-S study was designed to evaluate whether a sequential treatment of FOLFIRI [irinotecan plus 5-fluorouracil/folinic acid (5-FU/LV)] followed by docetaxel plus cisplatin improves disease-free survival in comparison with 5-FU/LV in patients with radically resected gastric cancer.

This study offers insight into how a more aggressive treatment regimen affects outcomes in this patient population.
READ FULL ARTICLE From Annals of Oncology

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs